共 102 条
[1]
Kim JM(2016)Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) Ann Oncol 27 1492-1504
[2]
Chen DS(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028
[3]
Garon EB(2014)Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 371 2189-2199
[4]
Rizvi NA(2017)Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet 389 255-265
[5]
Hui R(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1813
[6]
Snyder A(2018)Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma N Engl J Med 378 1277-1290
[7]
Makarov V(2019)Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger Ann Oncol 30 706-720
[8]
Merghoub T(2019)European association of urology guidelines on renal cell carcinoma: the 2019 update Eur Urol 75 799-810
[9]
Rittmeyer A(2019)NCCN guidelines insights: kidney cancer version 2 J Natl Compr Canc Netw 17 1278-1285
[10]
Barlesi F(2018)The immunobiology of kidney cancer J Clin Oncol 36 3547-3552